Global Digital Pathology Market Worth USD 1,052 Million by 2022
|
By LabMedica International staff writers Posted on 25 Jul 2016 |
The global digital pathology market will reach USD 1,052 million by 2022, driven by the growing popularity of virtual slides over physical slides, technological advancements, and cost-effective products, with North America accounting for the major share.
According to a new Allied Market Research (Portland OR, USA) report, other factors such as workflow efficiency, analysis efficiency, improved productivity and patient care, and accuracy are also contributing to the market growth. However, lack of reimbursement policies, inadequate infrastructure, and pending product approvals are restraining the growth of the global digital pathology market.
Digitalization of pathology, where glass slides are converted into digital images for easy viewing, analysis, storage, and management of collected data, has resulted in automation of tests during diagnosis, thus saving cost and efforts. For instance, pathologists can now perform tests using a single digital instrument instead of five instruments required earlier.
Based on product, the market is segmented into whole slide imaging (WSI), image analysis informatics, information management system storage & communication, and others. WSI is the major segment and is expected to grow at a CAGR of 14.8% from 2014 to 2022, due to its diversified use in surgical pathology, clinical diagnosis, consultation, and education, as well as in proficiency testing, which is a part of cytopathology.
Within the WSI segment, the scanners/digitizers segment accounted for the largest share in 2015, while reagents is projected to be the fastest growing segment at a CAGR of 15.3% from 2014 to 2022. The image analysis-informatics segment is the fastest growing segment, growing at a CAGR of 25.2%, and along with the WSI segment, it comprises about three-fourths of the total market.
Based on end user, the market is segmented into educational institutes, hospitals and diagnostic centers; and pharmaceutical & biotechnology companies. In 2015, hospitals and diagnostic centers and pharmaceutical & biotechnology end user segments together accounted for a share of more than 70% of the market. Pharmaceutical & biotechnology companies are projected to be the fastest growing end use segment, growing at a CAGR of 19.9% from 2014 to 2022.
In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In 2015, Asia Pacific and LAMEA together accounted for about 20% of the market. The German digital pathology market is expected to reach about USD50 million by 2022, growing at a CAGR of 14.5% over the period 2014 to 2022.
In 2015, North America accounted for the major share of the overall digital pathology market and is expected to grow at a CAGR of 14.7% from 2014 to 2022, driven mainly by a large number of hospitals and clinics adopting digital pathology procedures for accurate results and improved efficiency. In North America, WSI is expected to dominate the market followed by image analysis-informatics. However, Asia-Pacific is expected to grow rapidly at a CAGR of 26.6%, with the major contribution to come from China due to its cost-effective products and image analysis-informatics to be the fastest growing segment in the region with a CAGR of 34.9%.
Currently, companies are adopting collaborations, product launches, and agreements as their key development strategies in the market. An increase in the number of initiatives for commercializing cost-efficient digital pathology systems is expected to offer profitable growth opportunities for service providers in the future.
The key companies in the global digital pathology market are Definiens AG (Munich, Germany), Visiopharm (Hørsholm, Denmark), Indica Labs (Corrales, NM, USA), Digipath, Wichita, KS, USA), Danaher Corporation (Leica Microsystem) (Washington, D.C., USA), Koninklinje Philips N.V. (Amsterdam, Netherlands), Hamamatsu Photonics K. K. (Hamamatsu, Japan), PerkinElmer, Inc. (Waltham, MA; USA), Nikon Corporation (Tokyo, Japan), Pixcelldata Ltd. (Dublin 2, Ireland), and Glencoe Software Inc. (Seattle, WA, USA).
Related Links:
According to a new Allied Market Research (Portland OR, USA) report, other factors such as workflow efficiency, analysis efficiency, improved productivity and patient care, and accuracy are also contributing to the market growth. However, lack of reimbursement policies, inadequate infrastructure, and pending product approvals are restraining the growth of the global digital pathology market.
Digitalization of pathology, where glass slides are converted into digital images for easy viewing, analysis, storage, and management of collected data, has resulted in automation of tests during diagnosis, thus saving cost and efforts. For instance, pathologists can now perform tests using a single digital instrument instead of five instruments required earlier.
Based on product, the market is segmented into whole slide imaging (WSI), image analysis informatics, information management system storage & communication, and others. WSI is the major segment and is expected to grow at a CAGR of 14.8% from 2014 to 2022, due to its diversified use in surgical pathology, clinical diagnosis, consultation, and education, as well as in proficiency testing, which is a part of cytopathology.
Within the WSI segment, the scanners/digitizers segment accounted for the largest share in 2015, while reagents is projected to be the fastest growing segment at a CAGR of 15.3% from 2014 to 2022. The image analysis-informatics segment is the fastest growing segment, growing at a CAGR of 25.2%, and along with the WSI segment, it comprises about three-fourths of the total market.
Based on end user, the market is segmented into educational institutes, hospitals and diagnostic centers; and pharmaceutical & biotechnology companies. In 2015, hospitals and diagnostic centers and pharmaceutical & biotechnology end user segments together accounted for a share of more than 70% of the market. Pharmaceutical & biotechnology companies are projected to be the fastest growing end use segment, growing at a CAGR of 19.9% from 2014 to 2022.
In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In 2015, Asia Pacific and LAMEA together accounted for about 20% of the market. The German digital pathology market is expected to reach about USD50 million by 2022, growing at a CAGR of 14.5% over the period 2014 to 2022.
In 2015, North America accounted for the major share of the overall digital pathology market and is expected to grow at a CAGR of 14.7% from 2014 to 2022, driven mainly by a large number of hospitals and clinics adopting digital pathology procedures for accurate results and improved efficiency. In North America, WSI is expected to dominate the market followed by image analysis-informatics. However, Asia-Pacific is expected to grow rapidly at a CAGR of 26.6%, with the major contribution to come from China due to its cost-effective products and image analysis-informatics to be the fastest growing segment in the region with a CAGR of 34.9%.
Currently, companies are adopting collaborations, product launches, and agreements as their key development strategies in the market. An increase in the number of initiatives for commercializing cost-efficient digital pathology systems is expected to offer profitable growth opportunities for service providers in the future.
The key companies in the global digital pathology market are Definiens AG (Munich, Germany), Visiopharm (Hørsholm, Denmark), Indica Labs (Corrales, NM, USA), Digipath, Wichita, KS, USA), Danaher Corporation (Leica Microsystem) (Washington, D.C., USA), Koninklinje Philips N.V. (Amsterdam, Netherlands), Hamamatsu Photonics K. K. (Hamamatsu, Japan), PerkinElmer, Inc. (Waltham, MA; USA), Nikon Corporation (Tokyo, Japan), Pixcelldata Ltd. (Dublin 2, Ireland), and Glencoe Software Inc. (Seattle, WA, USA).
Related Links:
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







